Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15

Loading news article.

Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15 | WAPE

Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15

Article summary

Related companies

Comments —